NCT04407858Unknown不适用
Insuffisance Cardiaque Sous Carfilzomib: étude Prospective
European Georges Pompidou Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年5月21日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Incidence of cardio-vasculo-toxicity of carfilzomib
研究概览
简要总结
Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Intention to treat by Carfilzomib
排除标准
- •History of carfilzomib treatment
结局指标
主要结局
Incidence of cardio-vasculo-toxicity of carfilzomib
时间窗: 6 months
Number of patients with cardio-toxicity (composite endpoint) in a cohort of patients referred to a cardio-oncology before initiation of carfilzomib.
次要结局
- Systemic hypertension(6 months)
- Heart Failure Preserved Ejection Fraction(6 months)
- Heart Failure Reduced Ejection Fraction(6 months)
- Impact on outcomes(1 year)
- Safety(1 year)
- Predictors of Cardiotoxicity(6 months)
研究者
Mariana Mirabel
Associate Professor
European Georges Pompidou Hospital
研究点 (1)
Loading locations...
相似试验
终止
不适用
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive CarfilzomibDyspneaCardiotoxicityShortness of BreathMultiple MyelomaNCT04827563University of Chicago50
Unknown
1 期
Carfilzomib for the Prevention of Graft Versus Host DiseaseGraft-versus-host DiseaseNCT01991301Sheba Medical Center30
进行中（未招募）
1 期
Efficacy and safety of Carfilzomib in combination with Ibrutinib for patients with Waldenström's macroglobulinemia (CZAR-1)Waldenström's MacroglobulinemiaMedDRA version: 21.0Level: PTClassification code 10047801Term: Waldenstrom's macroglobulinaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003526-88-GRniversity Hospital Ulm184
招募中
1 期
Efficacy and safety of Carfilzomib in combination with Ibrutinib for patients with Waldenström's macroglobulinemia (CZAR-1)Waldenström's MacroglobulinemiaMedDRA version: 21.0Level: PTClassification code 10047801Term: Waldenstrom's macroglobulinaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003526-88-ATniversity Hospital Ulm103
招募中
2 期
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia
(CZAR-1)Waldenström’s Macroglobulinemia2024-511929-60-00Universitaetsklinikum Ulm AöR105